Almotriptan (Almogran) is a selective serotonin 1B/1D receptor agonist and an important drug in the clinical acute treatment of migraine attacks. As a triptan-class medication, there are many key aspects that require special attention during its use.

Precautions for Using Almotriptan (Almogran)

Scope of Applicable Populations

Almotriptan is mainly indicated for the acute treatment of migraine in adults, and can be used whether migraine is accompanied by aura symptoms or not.

For adolescent patients aged 12-17 years, it is only indicated for the treatment of migraine headache symptoms, and requires that the patients' untreated migraine attacks usually last for 4 hours or longer.

In the adolescent population, the efficacy of this drug for migraine-associated symptoms (such as nausea, photophobia, and phonophobia) has not been established.

Important restrictions include: It should only be used when migraine is clearly diagnosed; it is not applicable for the prophylactic treatment of migraine; and it is contraindicated for the treatment of cluster headaches.

Cardiovascular Contraindications

Almotriptan is strictly contraindicated in patients with ischemic heart disease, coronary artery vasospasm, or other significant cardiovascular diseases.

Such diseases include angina pectoris, history of myocardial infarction, asymptomatic ischemia, etc.

Patients with cerebrovascular syndromes (e.g., history of stroke or transient ischemic attack) and patients with peripheral vascular diseases (including ischemic enteropathy) are also among the contraindicated populations.

Contraindications Related to Drug Interactions

It is contraindicated in patients who have used ergotamine-containing or ergot-type drugs within 24 hours, including dihydroergotamine, ergotamine tartrate, methysergide, etc.

It must not be used in combination with other 5-HT1 receptor agonists (e.g., other triptan-class drugs) within 24 hours.

It is also contraindicated in patients with uncontrolled hypertension and those with a known allergy to any component of almotriptan.

Medication Monitoring for Almotriptan (Almogran)

Cardiovascular Event Monitoring

Severe cardiovascular adverse events such as severe coronary artery vasospasm and acute myocardial infarction may occur.

When patients experience symptoms such as chest pain or a feeling of pressure, they should seek medical attention immediately for evaluation.

For patients with risk factors for coronary heart disease, it is strongly recommended that the first dose be administered in a doctor's office.

Neurological Monitoring

Neurological adverse reactions such as dizziness, drowsiness, headache, and paresthesia may occur, and these are particularly common in adolescents.

Gastrointestinal Reaction Monitoring

The most common adverse reactions in adults include nausea and dry mouth, while nausea and vomiting are also relatively common in adolescents.